AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

23rd July 2021 Uncategorised 0

AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
nhigginsdunn
Fri, 07/23/2021 – 14:46

More: AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
Source: fierce